This post was authored by Martha Gulati, MD, MS, FACC, editor-in-chief of ACC’s CardioSmart.
The global diabetes epidemic continues to grow at an alarming pace. According to the World Health Organization, roughly 347 million people worldwide have diabetes, with deaths from diabetes expected to increase by more than 50 percent in the next decade. In the U.S. alone, a recent study estimates nearly half of adults have diabetes or prediabetes.
Diabetes also comes at a high price. The total national cost of diagnosed diabetes in the U.S. is $245 billion and the average medical expenditure among people with diabetes is more than two times higher than those without the disease. Further, indirect costs amount to $69 billion (disability, work loss and premature mortality). Continue reading
This post was authored by Darren McGuire, MD, FACC, a member of the Diabetes Collaborative Registry Steering Committee.
Until recently, the impact of antihyperglycemic medications on cardiovascular disease has been relatively unclear. However, a new class of antihyperglycemic medications called sodium glucose co-transporter (SGLT) 2 inhibitors is showing promise as a means of treating cardiovascular disease in patients with type 2 diabetes, and may change the way we consider antihyperglycemic treatment options for such patients.
The striking (and surprising) results of the EMPA-REG OUTCOME trial were all the buzz at the 2015 European Association for the Study of Diabetes Annual Meeting in Stockholm this past September. Data showed that empagliflozin, plus standard care, lowered the rate of the primary composite outcome of time to the first occurrence of death from cardiovascular causes, nonfatal myocardial infarction, or nonfatal stroke, in patients with type 2 diabetes and prevalent atherosclerotic cardiovascular disease at trial entry. Continue reading
This post was authored by ACC President Kim Allan Williams Sr., MD, FACC.
When it comes to diabetes education and support everyone has a role! As November kicks off Diabetes Awareness Month, it’s a good time to be mindful of the ACC tools and resources available to help you, as clinicians do your part to prevent and treat this disease that affects more than 30 million children and adults in the U.S. alone.
The Diabetes Collaborative Registry is one of the most exciting and ambitious new initiatives the College is involved in. In partnership with the Joslin Diabetes Center, American Diabetes Association, American Association of Clinical Endocrinologists and the American College of Physicians, our goal is to change the way diabetes is understood and treated. We feel strongly that by uniting primary care physicians, endocrinologists, cardiologists and other diabetes care providers we can make significant improvements in diabetes care and patient outcomes. Anyone can join the Diabetes Collaborative Registry for free. For practices already participating in the ACC’s PINNACLE Registry, the process is even easier and uses the same registry interface. Continue reading